Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 3/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.34 |
| ▸ | KDR | P35968 | 9/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769837 | 0.84 | APP (0.40) | LIMK1RPS6KA3CYP11B2 | |
| SCHEMBL12430648 | 0.70 | CYP2A6 (0.57) | CYP2A6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1769889 | 0.70 | CYP2A6 (0.45) | LIMK1LIMK2RPS6KA3CYP2A6CYP11B2 | |
| SCHEMBL1769970 | 0.65 | RPS6KA3 (0.46) | RPS6KA3CYP11B2 | |
| SCHEMBL13220241 | 0.64 | ESR1 (0.51) | CYP2A6TGFBR1 | |
| SCHEMBL2892375 | 0.63 | GAA (0.41) | RPS6KA3CYP2A6CYP11B2 | |
| SCHEMBL6922179 | 0.63 | CCNC (0.50) | RPS6KA3CYP11B2 | |
| SCHEMBL144441 | 0.63 | CYP2A6 (0.57) | CYP2A6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2175209 | 0.62 | CYP2A6 (0.47) | LIMK1RPS6KA3CYP2A6HDAC3HDAC1 | |
| SCHEMBL14282441 | 0.62 | ESR1 (0.45) | CYP2A6HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2993169-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2017-12-20 | — | — | EP | claimed |
| EP-2993169-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2016-03-09 | — | — | EP | claimed |
| EP-2993169-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-2993169-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-2993169-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2993169-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2501678-B1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8519134-B2 | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-08-27 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| CN-102712589-A | Aryl-pyridine derivatives as aldosterone synthase inhibitors | NOVARTIS AG | 2012-10-03 | — | — | CN | disclosed |
| EP-2501678-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061168-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316195-A1 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | LIMK1 2938/4885LIMK2 3136/4885RPS6KA3 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.